Respiratory syncytial virus (RSV) causes respiratory infections, often mild but that can be severe for newborns, elderly individuals with comorbidities, and immunocompromised patients. In pediatrics, it is the leading cause of bronchiolitis and pneumonia, with numerous annual hospitalizations in Switzerland. Among the elderly, RSV leads to significant morbidity. Prevention has advanced with the introduction of vaccines such as Arexvy and Abrysvo, as well as nirsevimab for infants. These innovations are expected to significantly reduce the burden of RSV in the coming years.